W U Kampen, B Boddenberg-Pätzold, M Fischer, M Gabriel, R Klett, M Konijnenberg, E Kresnik, H Lellouche, F Paycha, L Terslev, C Turkmen, F van der Zant, L Antunovic, E Panagiotidis, G Gnanasegaran, T Kuwert, T Van den Wyngaert
PURPOSE: Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain. METHODS: The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists...
October 20, 2021: European Journal of Nuclear Medicine and Molecular Imaging